Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial

Main Article Content

KA Papp
Probity Medical Research and K Papp Clinical Research, Waterloo, Ontario, Canada

M Lebwohl
Icahn School of Medicine at Mount Sinai, New York, New York, USA

AB Gottlieb
Icahn School of Medicine at Mount Sinai, New York, New York, USA

M Sebastian
Dermatological Practice Dr. med. Michael Sebastian, Mahlow, Germany

R Langley
Dalhousie University, Halifax, Nova Scotia, Canada

Y Okubo
Tokyo Medical University, Tokyo, Japan; 6UCB Pharma, Raleigh, North Carolina, USA

M Wang
UCB Pharma, Raleigh, North Carolina, USA

C Cioffi
UCB Pharma, Raleigh, North Carolina, USA

F Staelens
UCB Pharma, Braine-l?Alleud, Belgium

K Reich
Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf and Skinflammation? Center, Hamburg, Germany

Keywords

Plaque Psoriasis, Bimekizumab, Nail Psoriasis, Scalp Psoriasis, Palmoplantar Psoriasis

Abstract

Abstract not available.

References

1. Durham L. Curr Rheumatol Reports 2015;17:55

2. Fujishima S. Arch Dermatol Res 2010;302:499–505

3. Glatt S. Br J Clin Pharmacol 2017;83:991–1001

4. Papp KA. J Am Acad Dermatol 2018;79:277–86.e10

5. Reich K. AAD 2020 Oral Presentation

6. Merola JF. Dermatol Ther 2018;e12589.

Article Sidebar

Poster PDF
Published
Jan 1, 2021
DOI https://doi.org/10.25251/skin.5.supp.18

Article Details

How to Cite
Papp, K., Lebwohl, M., Gottlieb, A., Sebastian, M., Langley, R., Okubo, Y., Wang, M., Cioffi, C., Staelens, F., & Reich, K. (2021). Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial. SKIN The Journal of Cutaneous Medicine, 5(1), s18. https://doi.org/10.25251/skin.5.supp.18
Issue
Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Section
Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 > >>